GlaxoSmithKline Pharmaceuticals Q4 Results
- BSE: 500660
- NSE: GLAXO
- ISIN: INE159A01016
- Sector: Biotechnology & Drugs
BSE
2,830.05
-10.75 (-0.38%)
-10.75 (-0.38%)Volume3.76 K
Updated: Fri 11 Sep, 2026 | 15:29:35
NSE
2,818.90-22.00 (-0.77%)
-22.00 (-0.77%)Volume38.43 K
Updated: Fri 11 Sep, 2026 | 15:29:54
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 26
Note: Comparison is on QoQ basis
Quarterly - GlaxoSmithKline Pharmaceuticals Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 657.54 | 690.24 | -4.74% | 690.63 | 0.25% |
| Depreciation/ Amortization | 13.17 | 20.32 | -35.17% | 18.10 | -10.52% |
| Operating Income | 337.76 | 351.02 | -3.78% | 239.17 | 6.06% |
| Net Income | 277.86 | 295.62 | -6.01% | 194.48 | 5.70% |
| Other Operating Expenses Total | 135.63 | 154.22 | -12.06% | 132.58 | -0.47% |
| Net Income Before Taxes | 373.10 | 399.93 | -6.71% | 270.62 | 4.05% |
| Total Revenue | 995.30 | 1,041.26 | -4.41% | 929.80 | 2.15% |
| Selling/ General/ Admin Expenses Total | 164.75 | 151.88 | 8.48% | 172.83 | 7.70% |
| Diluted Normalized EPS | 16.40 | 16.67 | -1.57% | 11.37 | 5.73% |
EQUITY QUICK LINKS
FROM MARKETS
RELATED LINKS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.